Download PDF
Diabetologie und Stoffwechsel 2019; 14(05): 359-361
DOI: 10.1055/a-0947-2833
DDG-Preisträger
© Georg Thieme Verlag KG Stuttgart · New York

Psychodiabetologie – Hellmut-Otto-Medaille 2019 – eine Kurzübersicht der Preisträger Bernhard Kulzer und Norbert Hermanns

Bernhard Kulzer
  Forschungsinstitut der Diabetes-Akademie Bad Mergentheim (FIDAM)
,
Norbert Hermanns
  Forschungsinstitut der Diabetes-Akademie Bad Mergentheim (FIDAM)
› Author Affiliations
Further Information

Publication History

Publication Date:
06 November 2019 (online)

Also available at
    Permissions and Reprints

Wir freuen uns sehr über die Verleihung der Hellmut-Otto-Medaille der Deutschen Diabetes Gesellschaft, da wir beide Herrn Prof. Otto gut kannten und mit ihm völlig darin übereinstimmen, dass der Patient im Mittelpunkt der Therapie stehen und dementsprechend auch angemessen unterstützt werden muss. Sein Ansatz, die ambulante Schulung und praxenübergreifende Schulungsgemeinschaften zu fördern, war ein gemeinsames Anliegen, für das wir nicht selten gemeinsam durch die Republik getourt sind.

 

  • Literatur

  • 1 Kulzer B, Hermanns N. Diabetes als verhaltensmedizinische Erkrankung. In: Häring HU, Galwitz B, Müller-Wieland D. et al. (Hrsg) Diabetologie in Klinik und Praxis. 6.. Aufl. Stuttgart: Thieme-Verlag; 2011: 268-282
    Google Scholar
  • 2 Kulzer B, Hermanns N, Reinecker H. et al. Effects of self-management training in Type 2 diabetes: a randomized, prospective trial. Diabetic Medicine 2007; 24 (04) 415-423
    CrossrefPubMedGoogle Scholar
  • 3 Hermanns N, Kulzer B, Maier B. et al. The effect of an education programme (MEDIAS 2 ICT) involving intensive insulin treatment for people with type 2 diabetes. Patient Education and Counseling 2012; 86 (02) 226-232
    CrossrefPubMedGoogle Scholar
  • 4 Hermanns N, Ehrmann D, Schall S. et al. The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial. Diabetic Medicine 2017; 34 (08) 1084-1091
    CrossrefPubMedGoogle Scholar
  • 5 Hermanns N, Kulzer B, Ehrmann D. et al. The effect of a diabetes education programme (PRIMAS) for people with type 1 diabetes: results of a randomized trial. Diabetes Research and Clinical Practice 2013; 102 (03) 149-157
    CrossrefPubMedGoogle Scholar
  • 6 Ehrmann D, Bergis-Jurgan N, Haak T. et al. Comparison of the efficacy of a diabetes education programme for type 1 diabetes (PRIMAS) in a randomised controlled trial setting and the effectiveness in a routine care setting: Results of a comparative effectiveness study. PLoS One 2016; 11 (01) e0147581
    CrossrefPubMedGoogle Scholar
  • 7 Ehrmann D, Kulzer B, Schipfer M. et al. Efficacy of an education program for people with diabetes and insulin pump ireatment (INPUT): Results from a randomized controlled trial. Diabetes Care 2018; 41 (12) 2453-2462
    CrossrefPubMedGoogle Scholar
  • 8 Bergis D, Ehrmann D, Albrecht C. et al. Comparison of the efficacy of an education program for people with diabetes and insulin pump treatment (INPUT) in a randomized controlled trial setting and the effectiveness in a routine care setting: Results of a comparative effectiveness study. Patient Education and Counseling 2019; 102 (10) 1868-1874
    CrossrefPubMedGoogle Scholar
  • 9 Hermanns N, Ehrmann D, Schipfer M. et al. The impact of a structured education and treatment programme (FLASH) for people with diabetes using a flash sensor-based glucose monitoring system: Results of a randomized controlled trial. Diabetes Research and Clinical Practice 2019; 150: 111-121
    CrossrefPubMedGoogle Scholar
  • 10 Hermanns N, Kulzer B, Kubiak T. et al. The effect of an education programme (HyPOS) to treat hypoglycaemia problems in patients with type 1 diabetes. Diabetes Metabolism Research and Reviews 2007; 23 (07) 528-538
    CrossrefPubMedGoogle Scholar
  • 11 Hermanns N, Kulzer B, Krichbaum M. et al. Long-term effect of an education program (HyPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 2010; 33 (03) e36
    CrossrefPubMedGoogle Scholar
  • 12 Kulzer B, Hermanns N, Gorges D. et al. Prevention of diabetes self-management program (PREDIAS): effects on weight, metabolic risk factors, and behavioral outcomes. Diabetes Care 2009; 32 (07) 1143-1146
    CrossrefPubMedGoogle Scholar
  • 13 Peyrot M, Burns KK, Davies M. et al. Diabetes Attitudes Wishes and Needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. Diabetes Research and Clinical Practice 2013; 99 (02) 174-184
    CrossrefPubMedGoogle Scholar
  • 14 Nicolucci A, Kovacs Burns K, Holt RI. et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabetic Medicine 2013; 30 (07) 767-777
    CrossrefPubMedGoogle Scholar
  • 15 Kovacs Burns K, Nicolucci A, Holt RI. et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national benchmarking indicators for family members living with people with diabetes. Diabetic Medicine 2013; 30 (07) 778-788
    CrossrefPubMedGoogle Scholar
  • 16 Holt RI, Nicolucci A, Kovacs Burns K. et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national comparisons on barriers and resources for optimal care--healthcare professional perspective. Diabetic Medicine 2013; 30 (07) 789-798
    CrossrefPubMedGoogle Scholar
  • 17 Kulzer B, Lüthgens B, Landgraf R. et al. Diabetesbezogene Belastungen, Wohlbefinden und Einstellung von Menschen mit Diabetes – Deutsche Ergebnisse der DAWN2™-Studie. Diabetologe 2015; 11 (03) 211-218
    CrossrefGoogle Scholar
  • 18 Kulzer B, Lüthgens B, Landgraf R. et al. Wie belastend erleben Angehörige den Diabetes? Deutsche Stichprobe der internationalen DAWN2™-Studie. Diabetologe 2017; 13 (08) 570-580
    CrossrefGoogle Scholar
  • 19 Hermanns N, Schmitt A, Gahr A. et al. The effect of a Diabetes-Specific Cognitive Behavioral Treatment Program (DIAMOS) for patients with diabetes and subclinical depression: results of a randomized controlled trial. Diabetes Care 2015; 38 (04) 551-560
    PubMedGoogle Scholar
  • 20 Herder C, Hermanns N. Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes. Semin Immunopathol 2019; 41 (04) 477-489
    CrossrefPubMedGoogle Scholar
  • 21 Herder C, Schmitt A, Budden F. et al. Association between pro- and anti-inflammatory cytokines and depressive symptoms in patients with diabetes-potential differences by diabetes type and depression scores. Transl Psychiatry 2018; 7 (11) 1
    PubMedGoogle Scholar
  • 22 Herder C, Schmitt A, Budden F. et al. Longitudinal associations between biomarkers of inflammation and changes in depressive symptoms in patients with type 1 and type 2 diabetes. Psychoneuroendocrinology 2018; 91: 216-225
    CrossrefPubMedGoogle Scholar
  • 23 Heinemann L, Freckmann G, Ehrmann D. et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 2018; 391: 1367-1377
    CrossrefPubMedGoogle Scholar
  • 24 Hermanns N, Heinemann L, Freckmann G. et al. Impact of CGM on the management of hypoglycemia problems: Overview and secondary analysis of the HypoDE study. J Diabetes Sci Technol 2019; 13 (04) 636-644
    CrossrefPubMedGoogle Scholar
  • 25 Davies MJ, D'Alessio DA, Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41 (12) 2669-2701 . | Diabetologia 61(12): 2461–2498
    CrossrefPubMedGoogle Scholar
  • 26 Kulzer B, Daenschel W, Daenschel I. et al. Integrated Personalized Diabetes Management (PDM): Design of the ProValue studies. J Diabetes Sci Technol 2016; 10 (03) 772-781
    CrossrefPubMedGoogle Scholar
  • 27 Kulzer B, Daenschel W, Daenschel I. et al. Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program. Diabetes Research and Clinical Practice 2018; 144: 200-212
    CrossrefPubMedGoogle Scholar
  • 28 Heinemann L, Schramm W, Koenig H. et al. Benefit of digital tools used for integrated personalized diabetes management: Results from the PDM-ProValue study program. J Diabetes Sci Technol. 2019 Aug 5:1932296819867686. [Epub ahead of print]
    Google Scholar
  • 29 Heinemann L, Kulzer B. (Hrsg) Digitalisierungs- und Technologie-Report Diabetes. Mainz: Kirchheim-Verlag; 2019
    Google Scholar
  • 30 Kulzer B, Albus C, Herpertz S. et al. Psychosoziales und Diabetes (Teil 1). S2-Leitlinie Psychosoziales und Diabetes – Langfassung. Diabetologie und Stoffwechsel 2013; 8 (03) 198-242
    Article in Thieme ConnectGoogle Scholar
  • 31 Kulzer B, Albus C, Herpertz S. et al. Psychosoziales und Diabetes (Teil 1). S2-Leitlinie Psychosoziales und Diabetes – Langfassung. Diabetologie und Stoffwechsel 2013; 8 (04) 292-324
    Article in Thieme ConnectGoogle Scholar